Is the neonatal creatine phosphokinase level a reliable marker for fetal hypoxia?

2016 ◽  
Vol 43 (1) ◽  
pp. 114-121
Author(s):  
Mitsue Muraoka ◽  
Koichiro Takagi ◽  
Yoshihiro Morita ◽  
Hiroaki Nagano ◽  
Nobuhide Henmi ◽  
...  
Keyword(s):  
Creatine Phosphokinase ◽  
Fetal Hypoxia ◽  
Creatine Phosphokinase Level ◽  
Reliable Marker

An Iatrogenic Catatonia

2016 ◽  
Author(s):  
Robertus M. A. de Bie
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Creatine Phosphokinase ◽  
D2 Receptor ◽  
Disease Course ◽  
Atypical Neuroleptics ◽  
Altered Consciousness ◽  
Creatine Phosphokinase Level ◽  
Autonomic Instability ◽  
Increasing Temperature ◽  
Degrees Of Severity

Neuroleptic malignant syndrome is an iatrogenic movement disorders emergency characterized by rigidity, altered consciousness, and autonomic instability of varying degrees of severity. In severe cases this can be a fatal syndrome, so recognition and withdrawal of potentially causative medications is the priority. Management is otherwise supportive, and some patients will require admission to an intensive care unit. Creatine phosphokinase can be used to monitor the disease course; a decreasing creatine phosphokinase level with an increasing temperature may indicate an infection. The incidence of neuroleptic malignant syndrome has declined considerably with the increased use of atypical neuroleptics with greater D2 receptor blockade compared to older agents.

Lithium carbonate hypothyroidism, and serum creatine phosphokinase level

JAMA ◽  
1980 ◽  
Vol 243 (12) ◽  
pp. 1231a-1232
Author(s):  
V. Nair
Keyword(s):  
Creatine Phosphokinase ◽  
Lithium Carbonate ◽  
Serum Creatine Phosphokinase ◽  
Creatine Phosphokinase Level

scholarly journals Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

2010 ◽  
Vol 50 (12) ◽  
pp. 1568-1574 ◽  
Author(s):  
Sujata M. Bhavnani ◽  
Christopher M. Rubino ◽  
Paul G. Ambrose ◽  
George L. Drusano
Keyword(s):  
Randomized Trial ◽  
Creatine Phosphokinase ◽  
Level Data ◽  
Creatine Phosphokinase Level

Absence of myoglobinuria in acute psychotic patients with marked elevation in serum creatine phosphokinase level

2001 ◽  
Vol 11 (2) ◽  
pp. 111-115 ◽  
Author(s):  
Haggai Hermesh ◽  
Iris Manor ◽  
Roni Shiloh ◽  
Ronit Weizman ◽  
Hanan Munitz
Keyword(s):  
Creatine Phosphokinase ◽  
Marked Elevation ◽  
Serum Creatine Phosphokinase ◽  
Creatine Phosphokinase Level

scholarly journals Dynamics of clinical and laboratory indicators in serious patients and deaths with new coronavirus infection of COVID-19 under treatment of 8 mg dexamethasone

2021 ◽  
Vol 9 (1) ◽  
pp. 44-54
Author(s):  
V.I. Trykhlib ◽  
T.I. Lysenko ◽  
A.O. Yeroshenko ◽  
О.S. Martynchuk ◽  
K.P. Bieliaieva ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Creatine Phosphokinase ◽  
Viral Infections ◽  
Gradual Increase ◽  
Lactate Dehydrogenase Level ◽  
Gradual Decrease ◽  
Number Of Patients ◽  
Creatine Phosphokinase Level ◽  
Coronavirus Infection ◽  
Over Time

The article provides a review of the literature on the effectiveness of glucocorticoids in viral infections, including the new coronavirus infection COVID-19. The results of our research of the dynamics of laboratory parameters in patients who recovered and those who died are presented. The average age of patients who received 8 mg of dexamethasone and recovered was less than that of the deceased. The average day on which the patients were hospitalized in the ICU and who received 8 mg of dexamethasone in both groups was the same (on average on day 7). It is noteworthy that in patients who recovered, the febrile temperature was more often recorded before hospitalization, while in those who died it was more often subfebrile. The temperature during hospitalization in all categories of patients was on average at subfebrile numbers. The respiratory rate on admission in all categories of patients did not differ significantly and on average was about 19/min (up to 20/min was in 50 % of patients who recovered and 58.3 % of those who died). Those who recovered were more likely to have a normal heart rate on admission, but tachycardia was less common than within those who died. In patients who subsequently died, lower saturation levels were more often recorded upon admission. In the first 3 days after hospitalization, in patients who recovered and received 8 mg of dexamethasone, leukocytosis and granulocytosis were recorded more often; there was an increased number of stab neutrophils and the number of patients with it. The patients who subsequently died more often developed leukopenia, more pronounced lymphopenia with an increased quantity of patients with it; they presented more pronounced thrombocytopenia (the number of patients with it did not differ from those who recovered), higher erythrocyte sedation rate. In patients who subsequently died, during the observation period, there was a gradual increase in the number of leukocytes, but a gradual decrease in the number of lymphocytes, the creatine phosphokinase level increased from the 7th–9th days of hospitalization; on days 4–6 of hospitalization, the lactate dehydrogenase level significantly increased with its subsequent decline to a level that was greater than this in patients who recovered. Initially. The patients who recovered had an increase in leukocytes with their subsequent gradual decrease, a gradual increase in the level of lymphocytes, a decrease in the level of creatine phosphokinase, lactate dehydrogenase. In all categories of patients, a gradual decrease in the number of stab neutrophils was observed over time, a gradual increase in the number of platelets was also observed over time, but in those who recovered their level was slightly higher; in both groups, an increase in the urea level was observed over time, but in those who died its level from day 7 and later was significantly higher than in those who recovered; in patients in both groups, an increase in the level of creatinine was observed over time, but in those who died, its level from day 7 and later was significantly higher than in those who recovered; both groups showed a decrease in C-reactive protein over time, but those who died from the very beginning of their hospital stay and during all follow-up periods had higher levels than those who recovered.

scholarly journals Marked Elevation of the Creatine Phosphokinase Level in a Patient Receiving Tenofovir

2002 ◽  
Vol 35 (9) ◽  
pp. 1137-1137 ◽  
Author(s):  
K. D. Shere‐Wolfe ◽  
J. R. Verley
Keyword(s):  
Creatine Phosphokinase ◽  
Marked Elevation ◽  
Creatine Phosphokinase Level

scholarly journals A Curious Case of Acute Respiratory Failure: Is It Antisynthetase Syndrome?

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Gurveen Malhotra ◽  
Nitya Ramreddy ◽  
Serafin Chua ◽  
Mira Iliescu ◽  
Tanjeev Kaur
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Distress Syndrome ◽  
Creatine Phosphokinase ◽  
Clinical Presentation ◽  
Inflammatory Myopathies ◽  
Antisynthetase Syndrome ◽  
Amyopathic Dermatomyositis ◽  
Positive Serology ◽  
Creatine Phosphokinase Level

Antisynthetase (AS) syndrome is a major subgroup of inflammatory myopathies seen in a minority of patients with dermatomyositis and polymyositis. Although it is usually associated with elevated creatine phosphokinase level, some patients may have amyopathic dermatomyositis (ADM) like presentation with predominant skin involvement. Interstitial lung disease (ILD) is the main pulmonary manifestation and may be severe thereby determining the prognosis. It may rarely present with a very aggressive course resulting in acute respiratory distress syndrome (ARDS). We report a case of a 43-year-old male who presented with nonresolving pneumonia who was eventually diagnosed to have ADM through a skin biopsy without any muscle weakness. ADM may be associated with rapidly progressive course of interstitial lung disease (ADM-ILD) which is associated with high mortality. Differentiation between ADM-ILD and AS syndrome may be difficult in the absence of positive serology and clinical presentation may help in clinching the diagnosis.

The Myth of Elevated Serum Creatine Phosphokinase Level and Neuroleptic Malignant Syndrome

1991 ◽  
Vol 158 (5) ◽  
pp. 706-707 ◽  
Author(s):  
Adityanjee
Keyword(s):  
Case Report ◽  
Neuroleptic Malignant Syndrome ◽  
Creatine Phosphokinase ◽  
Case Reports ◽  
Elevated Serum ◽  
Original Description ◽  
Related Complication ◽  
Serum Creatine Phosphokinase ◽  
Creatine Phosphokinase Level ◽  
Recent Case Report

The 1980s witnessed the honeymoon between American psychiatry and an enigmatic and mysterious drug complication called neuroleptic malignant syndrome (NMS). I fear that the 1990s are witnessing the same in British psychiatry. Gone is the era when case reports in British literature described the syndrome without identifying it by name (Allan & White, 1972; Moyes, 1973), ostensibly owing to lack of awareness. Probably, no one had bothered to read the original description in the French-language literature (Delay et al, 1960). The pendulum has now swung to the other extreme. Every known drug-related complication is being labelled NMS. In the US, Addonizio et al (1986) suggested a ridiculously high incidence figure of 12.2%. The same trend for overdiagnosis is seen in the recent case report by Dalkin & Lee (1990). The authors of this case report seem to have forgotten that NMS is an idiosyncratic adverse drug reaction which is dose-independent. There is no reason to label every neuroleptic overdose as NMS on grounds of raised creatine phosphokinase (CPK) level.

Sign in / Sign up

Export Citation Format

Share Document